Snapdragon Chemistry Inc., a leader in flow chemistry process design and technology development, is pleased to announce their joining the Center for Continuous Manufacturing and Crystallization (CMAC) as a Tier 2 industry partner. Snapdragon will provide its expertise and access to its technologies to the center to help further CMAC’s research goals.

CMAC is a world-class national center delivering innovative ways to translate new molecules into high-value products. CMAC, led by the University of Strathclyde, has teams working in concert across seven UK universities. The center’s research is supported in part by the Engineering and Physical Sciences Research Council (EPSRC) and is informed by extensive engagement with national and global industry, end-users, technology providers, international academic programs and regulatory agencies. Additional support is realized through industrial partnerships including Tier 1 industry partners - GSK, AstraZeneca, Novartis, Bayer, Lilly, and Takeda.

As a Tier 2 partner Snapdragon Chemistry is proud to join and partner with the 17 Tier 2 technology companies, the 7 Tier 1 pharmaceutical companies and university research groups that share CMAC’s goal of revolutionizing how pharmaceuticals and high value products are made.

“We are delighted to join CMAC as a Tier 2 partner,” said Snapdragon Chemistry’s CEO Matthew Bio. “Academic/industrial partnerships like CMAC have demonstrated power in accelerating innovation and adoption in many technically challenging areas. Snapdragon Chemistry shares CMAC’s passion for creation and adoption of continuous manufacturing technologies which will undoubtedly lead to processes that deliver products in higher quality, with lower cost and improved sustainability.”